Glyburide
- Generic Name
- Glyburide
- Brand Names
- Diabeta, Glucovance, Glynase, Amglidia
- Drug Type
- Small Molecule
- Chemical Formula
- C23H28ClN3O5S
- CAS Number
- 10238-21-8
- Unique Ingredient Identifier
- SX6K58TVWC
- Background
Glyburide is a second generation sulfonylurea used to treat patients with diabetes mellitus type II. It is typically given to patients who cannot be managed with the standard first line therapy, metformin. Glyburide stimulates insulin secretion through the closure of ATP-sensitive potassium channels on beta cells, raising intracellular potassium and calcium ion concentrations.
Glyburide was granted FDA approval on 1 May 1984. A formulation with metformin was granted FDA approval on on 31 July 2000.
- Indication
Glyburide is indicated alone or as part of combination product with metformin, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus.
- Associated Conditions
- Gestational Diabetes Mellitus (GDM), Glycemic Control, Type 2 Diabetes Mellitus
Effect of Repaglinide on Postprandial Lipemia in Type 2 Diabetes
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2012-05-25
- Last Posted Date
- 2017-02-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 51
- Registration Number
- NCT01605773
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Houston, Texas, United States
A Comparison Between Two Oral Hypoglycemics - Metformin and Glybenclamide for the Treatment of Gestational Diabetes Mellitus
- Conditions
- Gestational Diabetes Mellitus
- Interventions
- First Posted Date
- 2012-03-26
- Last Posted Date
- 2016-11-01
- Lead Sponsor
- HaEmek Medical Center, Israel
- Target Recruit Count
- 108
- Registration Number
- NCT01563120
- Locations
- 🇮🇱
Dep. OB/GYN, Emek Medical Center, Afula, Israel
R230C and C230C Variants of ABCA1 and Glyburide Response
- First Posted Date
- 2011-10-21
- Last Posted Date
- 2014-01-15
- Lead Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- Target Recruit Count
- 85
- Registration Number
- NCT01456650
- Locations
- 🇲🇽
Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, DF, Mexico
Glyburide (RP-1127) for Traumatic Brain Injury (TBI)
- First Posted Date
- 2011-10-18
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Remedy Pharmaceuticals, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT01454154
- Locations
- 🇺🇸
UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸University of Maryland Medical Center, Shock Trauma Center, Baltimore, Maryland, United States
🇺🇸University of California, San Diego, San Diego, California, United States
Glyburide and Metformin for Gestational Diabetes Mellitus (GDM)
- Conditions
- Gestational Diabetes Mellitus
- Interventions
- First Posted Date
- 2011-04-05
- Last Posted Date
- 2015-02-10
- Lead Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Target Recruit Count
- 360
- Registration Number
- NCT01329016
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
🇺🇸University of Texas Medical Branch, Galveston, Texas, United States
🇺🇸University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Vitamin C Supplementation Plus Hypoglycemic Agents Versus Hypoglycemic Agents Alone in Type 2 Diabetes Mellitus
- First Posted Date
- 2011-03-22
- Last Posted Date
- 2013-09-18
- Lead Sponsor
- Al-Neelain University
- Target Recruit Count
- 50
- Registration Number
- NCT01319734
- Locations
- 🇸🇩
Jaber abo aliz, Khartoum, Sudan
Glyburide Advantage in Malignant Edema and Stroke Pilot
- First Posted Date
- 2010-12-31
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Remedy Pharmaceuticals, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT01268683
- Locations
- 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Evaluation of Cissus Verticillata L. Infusion in Controlling Type 2 Diabetes
- First Posted Date
- 2010-06-16
- Last Posted Date
- 2011-11-09
- Lead Sponsor
- Federal University of Paraíba
- Target Recruit Count
- 15
- Registration Number
- NCT01145534
- Locations
- 🇧🇷
Centro de Especialidades Odontologicas, Patos, Paraiba, Brazil
Safety Study of RP-1127 (Glyburide for Injection) in Healthy Volunteers
- Conditions
- Traumatic Brain InjuryStroke
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-05-28
- Last Posted Date
- 2021-06-21
- Lead Sponsor
- Biogen
- Target Recruit Count
- 34
- Registration Number
- NCT01132703
- Locations
- 🇺🇸
Jasper Clinic, Kalamazoo, Michigan, United States
A Study of LY2599506 (Oral Agent Medication: Glucokinase Activator 1) in Type 2 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2009-12-10
- Last Posted Date
- 2011-12-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 38
- Registration Number
- NCT01029795
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Teruel, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.